title: Community acquired pneumonia caused by Chlamydia pneumoniae strain TWAR in chronic cardiopulmonary disease in the elderly.
abstract: The role of Chlamydia pneumoniae in respiratory infections is controversial. Seroepidemiological studies in different countries have shown an incidence of around 50% of previous contact, whereas prospective studies only in the USA have detected 6-10% of C. pneumoniae in community acquired pneumonias; in a similar Swedish study no cases were detected. There have been no descriptions of this Chlamydia in Mediterranean countries. The acute antibody response indicative of recent infection is accepted if the microimmunofluorescence test shows a fourfold rise in antibody or a titer 1/6 or higher of the IgM fraction. Since the introduction of the microimmunofluorescence test in our hospital, we have detected 4 cases of pneumonia associated to TWAR antibody in a current study of 63 cases of community acquired pneumonias which required hospitalization. All 4 patients presented chronic cardiopulmonary diseases. These facts and additional seroepidemiological studies with a frequency of 53% of previous contact, show that C. pneumoniae has a nonrare etiology in Spain and could be an endemic condition.
authors.affiliation: Servicio de Neumología, Hospital Ramóny y Cajal, Madrid, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Pacheco
authors.forename: J
authors.initials: J
authors.lastname: González-Sainz
authors.forename: C
authors.initials: C
authors.lastname: Arocena
authors.forename: M
authors.initials: M
authors.lastname: Rebollar
authors.forename: A
authors.initials: A
authors.lastname: Antela
authors.forename: A
authors.initials: A
authors.lastname: Guerrero
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000907:Antibodies, Bacterial / Q000032:analysis; D002690:Chlamydia Infections / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology*; D016993:Chlamydophila pneumoniae / Q000276:immunology / Q000302:isolation & purification*; D002908:Chronic Disease; D004917:Erythromycin / Q000627:therapeutic use; D005260:Female; D006331:Heart Diseases / Q000150:complications; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000150:complications; D008297:Male; D011014:Pneumonia / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology*; D011446:Prospective Studies
chemical_list: D000907:Antibodies, Bacterial; D004917:Erythromycin